Drugs & Targets Exact Sciences to acquire Ashion Analytics, enter research collaboration with City of Hope’s Genomics Institute, TGen February 19, 2021Vol.47 No.07
Drugs & Targets Ukoniq receives FDA accelerated approval for marginal zone lymphoma and follicular lymphoma February 12, 2021Vol.47 No.06
Drugs & Targets Breyanzi receives FDA approval for adults with relapsed or refractory large-B-cell lymphoma February 12, 2021Vol.47 No.06
Drugs & Targets Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma February 12, 2021Vol.47 No.06
Drugs & Targets MD Anderson, Mirati Therapeutics collaborate on KRAS and solid tumor research February 12, 2021Vol.47 No.06
Drugs & Targets Inrebic received European Commission approval for myelofibrosis February 12, 2021Vol.47 No.06
Drugs & TargetsFree FDA grants accelerated approval to Tepmetko for metastatic NSCLC February 05, 2021Vol.47 No.05
Drugs & TargetsFree Keytruda receives positive EU CHMP opinion for expanded approval in some cases of relapsed or refractory classical hodgkin Lymphoma February 05, 2021Vol.47 No.05
Drugs & TargetsFree Opdivo + Cabometyx receives FDA approval for advanced renal cell carcinoma January 29, 2021Vol.47 No.04
Drugs & TargetsFree European Commission approves Keytruda as first-line treatment in adult patients with MSI-H or dMMR colorectal cancer January 29, 2021Vol.47 No.04
